Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems

Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in 2022. The majority (80%) of lung cancer cases belong to the non-small cell lung carcinoma (NSCLC) subtype. Despite the increased screening efforts, the median five-year survival of metastatic NSCLC remains...

Full description

Bibliographic Details
Main Authors: George Doumat, Darine Daher, Morgan Bou Zerdan, Nasri Nasra, Hisham F. Bahmad, Monica Recine, Robert Poppiti
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Current Oncology
Subjects:
drug repurposing
non-small cell lung cancer
therapy resistance
review
Online Access:https://www.mdpi.com/1718-7729/30/1/55

Internet

https://www.mdpi.com/1718-7729/30/1/55

Similar Items